Loading...
InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naive disease - An International Rare Cancers Initiative (IRCI) trial
Rao, S Sclafani, F Eng, C Guren, MG Adams, RA Benson, A Sebag-Montefiore, D Segelov, E Bryant, A Peckitt, C
Rao, S
Sclafani, F
Eng, C
Guren, MG
Adams, RA
Benson, A
Sebag-Montefiore, D
Segelov, E
Bryant, A
Peckitt, C
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 111.46 KB
Keywords
Type
Meetings and Proceedings
Citation
Rao S, Sclafani F, Eng C, Gr�nlie Guren M, Adams RA, Benson A, et al. LBA21 InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment na�ve disease - An International Rare Cancers Initiative (IRCI) trial. Annals of Oncology. 2018;29(suppl_8).